TKI-conditioned immunotherapy using -inactivated reovirus promotes survival in hepatocellular carcinoma, mediated by cytotoxic CD4 T-cells

Russell Hughes,Amy Moran,Karen J. Scott,Elizabeth Appleton,Matthew J. Bentham,Elizabeth Ilett,Alan Melcher,Andrew Macdonald,Adel Samson,Stephen Griffin

DOI: https://doi.org/10.1101/2024.02.23.581738

2024-02-23

Abstract:Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths worldwide. Whilst immunotherapy combination regimens are now standard of care for advanced HCC, tyrosine kinase inhibitors (TKIs), such as the former first-line agent sorafenib, remain an important choice for those unable to tolerate immunotherapies but provide marginal efficacy. Therefore, we sought to determine whether the efficacy of sorafenib could be enhanced by combining it with human , an oncolytic virus possessing immunostimulatory properties. We discovered that -inactivated, replication-deficient reovirus, not live virus, significantly extended the survival of mice bearing HCC tumors when combined with sorafenib. This response was characterised by increased intra-tumoral expression of both CCL5 and IFNB, and a skewing of the T-cell ratio in favor of non-canonical, CD4 cytotoxic T-cells expressing granzyme B, but perforin. This study highlights both the therapeutic potential of -reovirus in TKI-conditioned HCC and the often-overlooked contributions of non-classical immune mechanisms to therapeutic success.

Immunology

What problem does this paper attempt to address?

The problem this paper attempts to address is: how to enhance the therapeutic effect on hepatocellular carcinoma (HCC) by combining the tyrosine kinase inhibitor (TKI) sorafenib with ultraviolet-inactivated reovirus (uv-Reo). Specifically, the study aims to explore whether this combination therapy can extend the survival of tumor-bearing mice and inhibit tumor growth by activating non-classical immune mechanisms, particularly by promoting the function of non-classical cytotoxic CD4+ T cells.

The paper points out that although immune checkpoint inhibitor (ICI) combination therapy has become the standard treatment for advanced HCC, some patients are limited to TKI treatment, such as sorafenib, due to their inability to tolerate ICI therapy. However, the efficacy of sorafenib is limited, necessitating new methods to enhance its effectiveness. This study experimentally found that the combined use of uv-Reo and sorafenib not only significantly extended the survival of tumor-bearing mice but also induced an anti-tumor immune response dominated by non-classical cytotoxic CD4+ T cells. These cells express granzyme B (GZMB) but not perforin and exert their anti-tumor effects in a contact-dependent manner. Additionally, this therapy promoted the expression of CCL5 in the tumor microenvironment, further enhancing the infiltration of CD4+ T cells, thereby improving the therapeutic effect.